Unusual forms of XXXX .

@entity662 @entity1 @entity172 @entity301 @entity1112 @entity409 @entity1163 @entity3988 @entity1200 @entity951 @entity842 @entity74 @entity741 @entity453 @entity460 @entity731 @entity943
Unusual forms and causes of @entity741 include @entity951 in the presence of normal coronary arteries ( @entity1112 ), @entity301 , @entity74 , and graft @entity731 after cardiac transplantation. There is now evidence that @entity409 of coronary resistance vessels can account for abnormalities of the coronary microvasculature and possibly, @entity741 and @entity662 . The incidence of @entity1112 appears to be higher in @entity1 , particularly those who have undergone hysterectomy. An intriguing hypothesis is that low @entity172 levels may be associated with reduced expression of @entity842 (reflecting @entity409 ). The presence of @entity301 in the young should not be underestimated. @entity1163 and @entity943 are observed frequently in this @entity1 population and warrant vigorous exploration. Worldwide, cardiac transplantation is now carried out in approximately 4500 @entity1 yearly, with excellent (80% to 90%) 1-year survival due to improved immunosuppression. However, accelerated @entity731 develops rapidly postoperatively and is the main cause of late death. The link between cellular rejection of the myocardium and transplant @entity453 is not clear. The process of transplant @entity453 is believed to be due to chronic @entity1200 followed by intimal smooth-muscle proliferation and lipid deposition in the vascular wall. By the time it is detected by coronary angiography, the disease is far advanced and not susceptible to routine revascularization procedures. A prospective, randomized study of @entity3988 versus no @entity460 blocker started early after transplantation has documented highly significant reductions in transplant @entity731 as measured by lumen narrowing, clinical events, and rates of retransplantation or death due to the process.(ABSTRACT TRUNCATED AT 250 WORDS)
